TaiwanJ
景凱生物科技股份有限公司
TaiwanJ is a Taiwan Emerging Stock Board biotechnology company, as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| JKB-122 | — | Phase 2; completed | Autoimmune Hepatitis | United States | 2020-07-21 | Trial registry |
Key events
No verified events in the past twelve months.
Related Drugnews articles
No related articles in this language.